Astellas Pharma Inc. and Seattle Genetics, Inc. have presented first clinical data for ASG-15ME and ASG-22ME at the American Society of Clinical Oncology (ASCO) 51st Annual Meeting that was held in June 3-7, 2016 in Chicago, IL. ASG-15ME and ASG-22ME are investigational antibody-drug conjugates (ADCs) consisting of monoclonal antibodies that are designed to supply microtubule-disrupting agents selectively to tumor cells. This process is intended to spare non-targeted cells and thus minimize many of the toxic effects of traditional chemotherapy, in addition to enhance antitumor activity. ASG-15ME and ASG-22ME target SLITRK6 and Nectin-4, respectively. These are proteins that are highly expressed in urothelial cancers, particularly bladder cancer.
Len Reyno, M.D, senior vice president and chief medical officer, Agensys, an affiliate of Astellas, said: “Bladder cancer is the fifth most common cancer in the U.S. and there have been few treatment advances over the past three decades. For metastatic disease, the five-year survival rate is only 15 percent, representing a significant unmet need to identify additional treatment options. We are pleased to present these first data for ASG-15ME and ASG-22ME in urothelial cancers, which have a particularly high unmet medical need.”
“The clinical data from the phase I presented at ASCO from the ASG-15ME and ASG-22ME programs in heavily pretreated metastatic bladder cancer patients show a manageable safety profile along with objective response rates that are higher than historical rates seen with taxanes. We will continue enrolling patients in the ongoing phase 1 clinical trials to determine the recommended dose for further development,” said Jonathan Drachman, M.D., chief medical officer and executive vice president, Research and Development at Seattle Genetics.
Astellas and Seattle Genetics Present ASG-15ME and ASG-22ME Phase I Clinical Data in Metastatic Urothelial Cancerlast edit: 2016-06-22T17:46:33+00:00da